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A B S T R A C T
Purpose
CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European
populations; however, there are limited data on risk of breast cancer by age and tumor subtype,
which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype-
and age-speciﬁc risk estimates by using data from the Breast Cancer Association Consortium,
including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for
CHEK2*1100delC.
Patients and Methods
CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds
ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic
regression and adjusted for study (categorical) and age. Main analyses included patients with in-
vasive breast cancer from population- and hospital-based studies.
Results
Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer
from population- and hospital-based studies, and in patients with breast cancer from familial- and
clinical genetics center–based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR
for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 3 10220). The OR was higher for
estrogen receptor (ER)–positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.93 10221]) than it was for
ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 3 1024). The OR
signiﬁcantly declinedwith attained age for breast cancer overall (P= .001) and for ER-positive tumors
(P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by
age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%,
respectively, in the general population of the United Kingdom.
Conclusion
TheseCHEK2*1100delC breast cancer risk estimates provide a basis for incorporatingCHEK2*1100delC
into breast cancer risk prediction models and into guidelines for intensiﬁed screening and follow-up.
J Clin Oncol 34:2750-2760. © 2016 by American Society of Clinical Oncology
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INTRODUCTION
Susceptibility to breast cancer is known to be conferred by rare
mutations in high-risk genes, notably BRCA1 and BRCA2, by
mutations in several moderate-risk genes, and by a large number of
common genetic variants. Among moderate-risk genes, one of the
best established is CHEK2 (cell-cycle checkpoint kinase 2).1 The
protein encoded by CHEK2 is a cell-cycle checkpoint regulator and
putative tumor suppressor and it plays a critical role in the DNA
damage repair pathway.2-4 The 1100delC germlinemutation inCHEK2,
which is located at 22q12.1 (NM_007194.3(CHEK2):c.1100del:
p.(Thr367Metfs*15)), is themost frequently found protein-truncating
variant in populations of European descent.1,5-7 Deletion of a single
cytosine at position 1100 in exon 10 introduces a stop codon and
results in a kinase-dead CHEK2 protein.
Although the evidence that CHEK2*1100delC is associated
with increased breast cancer risk is unequivocal, the magnitude of
the risk is still uncertain, in part because the variant is relatively
uncommon and in part because many studies have oversampled
cases with a family history of disease, which leads to biased results.
Published relative risk estimates forCHEK2*1100delC carriers vary
between 1.5 and 3.7-10 The largest meta-analysis of breast cancer
risk forCHEK2*1100delC estimated an odds ratio (OR) of 2.7 (95%CI,
2.1 to 3.4) on the basis of unselected breast cancer cases and an almost
two times higherORon the basis of on familial breast cancer cases (OR,
4.8; 95% CI, 3.3 to 7.2).7 Although CHEK2*1100delC carriers tend
to develop estrogen receptor (ER)–positive tumors, they have a worse
breast-cancer speciﬁc survival compared with noncarriers.8,11-14
CHEK2*1100delC is also associated with a higher risk for contra-
lateral breast cancer.9,11,12,15We previously showed that, especially in
countries with a high prevalence of CHEK2*1100delC, this variant
occurred relatively frequently in population-based young patients
with breast cancer1,7,11; however, no unbiased age-speciﬁc risk es-
timates have been reported so far for CHEK2*1100delC carriers.
In the last few years, clinical genetic testing of women to
estimate future risk of breast cancer has progressed beyond BRCA1
and BRCA2 testing to the use of gene panel testing, which involves
the simultaneous testing of many known or suspected suscepti-
bility genes, including CHEK2.16 Such clinical testing, however,
need to be underpinned by reliable risk estimates. Moreover,
screening and prevention strategies are age dependent and driven
by such factors as family planning,17 and, hence, require reliable
age-speciﬁc risks. In addition, knowledge about subtype-speciﬁc
risks may be relevant for breast cancer prevention strategies.18 The
aim of the current study, therefore, was to provide age- and tumor
subtype–speciﬁc risk estimates by using data from the Breast
Cancer Association Consortium (BCAC), which includes. 85,000
women who have been genotyped for CHEK2*1100delC.
PATIENTS AND METHODS
Patient and Clinical Data Collection
From 36 studies in the BCAC, 96,489 persons were genotyped for
CHEK2*1100delC. After exclusion of non-Europeans and males, 91,147
women from 35 studies remained, including 930 heterozygous and 15
homozygous CHEK2*1100delC carriers (Appendix Table A1, online only;
Appendix Fig A1, online only). Two studies in which fewer than three
CHEK2*1100delC carriers were detected were excluded from further risk
analyses, which left 42,977 controls and 44,777 patients with breast cancer
from 33 studies (Appendix Fig A1). Genotype data from ﬁve studies had
been included in a previous meta-analysis,1 but the majority of data were
generated in a new genotyping experiment. Studies were classiﬁed according
to sampling frame for the cases and controls into population- and hospital-
based studies (unselected for family history) or clinical genetics–based and
familial studies. Data on patient characteristics—age, family history, and
BRCA1/2 mutation status—and tumor characteristics had also been sub-
mitted by individual studies and were centrally harmonized and checked
according to a standard data dictionary (Data Supplement). Details of
the studies have been published previously (Appendix Table A1),19,20
and a subset of the data has been previously used for an analysis of
CHEK2*1100delC and disease outcome.12 All studies were approved by
the relevant institutional review boards, and participants provided
written informed consent or did not object to the secondary use of their
tissue and data following country-speciﬁc regulations.21
CHEK2*1100delC Genotyping
Details of CHEK2*1100delC genotyping performed in the 35 Eu-
ropean studies included are shown in the Data Supplement and in Ap-
pendix Table A1. Genotyping of the majority of samples (n = 84,314) was
done by using a 59exonuclease Taqman allelic discrimination assay de-
veloped by the Netherlands Cancer Institute–Antoni van Leeuwenhoek
Hospital. Primers for the custom Taqman assay were speciﬁcally designed
to be nonbinding to the pseudogenes on chromosomes 15 and 16, which
are homologous to exons 10 to 14 of CHEK2 on chromosome 22. An
additional 6,833 samples were genotyped by using a different Taqman,
iPlex, or oligohybridization assay.
Statistical Analyses
Primary analyses were performed by using STATA (version SE11.2;
STATA, College Station, TX; Computing Resource Center, Santa Monica,
CA), and calculation of cumulative risks, estimates of frequency by
country, and graphics in Figures 1 and 2 were performed in R (version
3.2.1; R Foundation for Statitiscal Computing, Vienna, Austria). P values
reported are two-sided, and P values , .05 were considered signiﬁcant.
Differences between proportions were tested by using the Pearson x2 test,
Fisher’s exact test was used for comparisons that included cells with fewer
than ﬁve observations, and differences and between mean ages were tested
by using the t test. Breast cancer ORs for CHEK2*1100delC carriers versus
noncarriers were estimated by using logistic regression. All variables were
included in analyses as categorical, as indicated in the tables, except for age
(continuous in years). All analyses were adjusted for study (categorical). We
compared a carrier model—homozygous and heterozygousCHEK2*1100delC
carriers were combined—and a log-additive model, including a linear term of
the number of 1100delC alleles, with a saturated model by using likelihood
ratio tests. Because no homozygous carriers were observed in controls, the
saturated model did not converge, and we determined the likelihood by
considering a range of possible values for the homozygote risk—between 5 and
20, in 1-point increments—by using an offset term.
The main analyses focused on the comparison of patients with breast
cancer recruited through population- and hospital-based studies. We
performed sensitivity analyses that excluded known BRCA1/2 carriers,
in situ and unknown behavior breast cancers, prevalent breast cancers
(from patients whose blood was sampled . 1 year after diagnosis), and
samples for which CHEK2*1100delC genotypes were obtained with assays
other than the custom Taqman. Subgroup case-control analyses were
performed by age, family history, and tumor subtype of patients with
breast cancer. To assess statistical signiﬁcance of differences between
subgroups, we compared these subgroups in a case-only analysis with
CHEK2 as the dependent variable. For the forest plot (Appendix Fig A2,
online only), the summary estimate was derived from a ﬁxed effect
meta-analysis of the log(OR) estimates from individual studies by using
the inverse variance method (ﬁxedi in STATA).
www.jco.org © 2016 by American Society of Clinical Oncology 2751
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Country
0 0.002 0.004 0.006 0.008 0.010 0.015
Frequency Rate 95% CI
Australia 0.0020 to 0.0044
Belarus 0.0020 to 0.0047
Belgium 0.0030 to 0.0075
Canada 0.0025 to 0.0099
Denmark 0.0053 to 0.0081
Finland 0.0100 to 0.0152
Germany 0.0044 to 0.0066
Ireland 0.0009 to 0.0038
The Netherlands 0.0110 to 0.0162
Norway 0.0031 to 0.0063
Poland 0.0017 to 0.0036
Russia 0.0010 to 0.0038
Sweden 0.0032 to 0.0065
UK 0.0047 to 0.0062
USA
0.0030
0.0030
0.0047
0.0049
0.0066
0.0124
0.0054
0.0018
0.0134
0.0044
0.0024
0.0020
0.0046
0.0054
0.0037 0.0028 to 0.0050
Fig 1. CHEK2*1100delC frequency rates per country in legend are shownwith 95% conﬁdence intervals andwere calculated using amodiﬁcation of the empirical Bayes
approach proposed by Clayton and Kaldor, as described in the methods. Analysis included all controls (44,276 non-carriers and 235 CHEK2*1100delC carriers) and all
population- and hospital-based breast cancer patients (38,783 non-carriers and 502 CHEK2*1100delC carriers). When the breast cancer patients from the clinical genetics
and familial studies were also included, the rates slightly changed, but not the color of the countries in the map (results not shown).
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In addition, we modeled the CHEK2*1100delC breast cancer risk
estimates by age by using the more stable interaction estimates for age
and CHEK2*1100delC from the case-only analysis (Data Supplement).
Cumulative risks were calculated on the basis of estimated relative
breast cancer risks for CHEK2*1100delC carriers by using United
Kingdom breast cancer incidences from 1992 to 2010 and the ratio of
ER-positive and ER-negative breast tumors from the BCAC database
(Data Supplement). Carrier frequency estimates by country were de-
rived by using a modiﬁcation of the empirical Bayes approach proposed
by Clayton and Kaldor22 for mapping disease incidence rates (Data
Supplement).
RESULTS
Analyses included 42,977 controls and 44,777 patients with breast
cancer from 33 BCAC studies, of which 42,627 patients were
recorded as having invasive tumors as well as 1,734 with in situ
tumors (Appendix Fig A1). We included in the analysis only
European women who had been genotyped for CHEK2*1100delC
because this mutation is rare in other ethnicities23; we detected
only three carriers of the mutation in non-Europeans. Summaries
of patient and tumor characteristics by study are shown in Ap-
pendix Tables A2 to A6 (online only), and characteristics of
CHEK2*1100delC carriers and noncarriers are summarized in
Appendix Table A7 (online only).
CHEK2*1100delC Heterozygous and Homozygous
Carriers
Proportions of CHEK2*1100delC carriers in controls, patients
with breast cancer from population- or hospital-based studies, and
patients from familial or clinical genetics center–based studies were
0.5%, 1.3%, and 3.0% respectively (Appendix Table A7). Ho-
mozygous CHEK2*1100delC carriers were rare (n = 15; 0.02%)
and occurred only in cases. Ten of 15 homozygous carriers were
identiﬁed in studies from the Netherlands (Appendix Table A1,
online only). The frequency of CHEK2*1100delC in women
of European descent displayed wide variation by country,
from. 1.2% in the Netherlands and Finland to, 0.3% in Eastern
Europe (Fig 1).
Comparison of a carrier model in which both homozygous
and heterozygous CHEK2*1100delC were deﬁned as carriers,
with a saturated model (see Patients and Methods) indicated
a higher risk estimate for homozygous than heterozygous carriers
(P = .017 on the basis of population- and hospital-based studies;
Appendix Table A8, online only). A log-additive model could not
be rejected (P = .10 compared with the saturated model);
however, the estimated ORs for heterozygotes were similar in the
three models. Because homozygous carriers were rare and it
would not be possible to obtain reliable estimates for age- and
tumor subtype–speciﬁc analyses, we excluded the 15 homozygous
carriers so that subsequent risk estimates refer to heterozygous
carriers.
Tumor Characteristics of CHEK2*1100delC Carriers
CHEK2*1100delC patients with breast cancer from pop-
ulation- and hospital-based studies were younger and more often
developed ER-positive and progesterone receptor (PR)–positive
tumors, although carriers and non-carriers were similar with
respect to morphology, grade, and human epithelial growth factor
receptor 2 (HER2) status (Table 1); results for the clinical genetic
and familial studies were similar. CHEK2*1100delC patients with
breast cancer from population- and hospital-based studies more
often developed in situ tumors. We suspected that the association
between CHEK2*1100delC and in situ tumors could be a result of
differential recruitment related to family history of breast cancer
and screening. In support of this hypothesis, there was evidence of
an association between CHEK2*1100delC and ﬁrst-degree family
history of breast cancer for women with in situ cancers (P = .05),
but not for invasive tumors (P = .85; using logistic regression
analysis adjusted for study). No such associations were observed
for patients with breast cancer in clinical genetic and familial studies.
In controls, there was no association between CHEK2*1100delC
carriership and family history (n = 41,529; OR, 1.00; 95%CI, 1.00
to 1.00; P = .77) or age (n = 38,358; OR, 1.00; 95% CI, 0.99 to
1.01; P = .99).
Overall Breast Cancer Risk Estimates and Sensitivity
Analyses
Breast cancer risk estimates for CHEK2*1100delC carriers,
including various sensitivity analyses, are shown in Table 2. ORs for
breast cancer of any behavior (in situ or invasive) and inva-
sive breast cancer were 2.32 (95%CI, 1.95 to 2.75; P = 5.53 10222)
and 2.26 (95%CI, 1.90 to 2.69; P = 2.33 10220), respectively, using
population- and hospital-based studies. There was no evidence
of heterogeneity in ORs among the studies (Appendix Fig A2).
The OR based on all breast cancers, including those from fa-
milial and clinical genetics center-based studies, was higher
(OR = 2.44; 95% CI, 2.08 to 2.87; P = 6.3 3 10228), consistent
with overrepresentation of cases with a family history of dis-
ease. The OR based on incident breast cancers only was lower
(OR = 2.11; 95% CI, 1.69 to 2.65; P = 6.33 10211); in case-only
analysis this was signiﬁcantly different from the OR for prevalent
tumors (P = 1.5 3 1024).
30
0
1
2
3
4
40 50 60 70 80
Age (years)
OR
Overall
ER-positive
ER-negative
Fig 2. Breast cancer relative risk curves for CHEK2*1100delC carriers by age for
invasive breast cancer: overall, estrogen receptor (ER)–positive, and ER-negative
disease. OR, odds ratio.
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Subgroup Breast Cancer Risk Estimates
Table 3 gives breast cancer risk estimates for CHEK2*1100-
delC carriers by patient subgroup and by tumor subtype. The OR
was higher for women without a ﬁrst-degree relative with breast
cancer compared with those with a family history, but not sig-
niﬁcantly so (P = .31). Moreover, this analysis included two studies
with outlier results that were caused by the study deﬁnitions that
were used (Appendix Table A6). Excluding these two studies, ORs
for women without and with a ﬁrst-degree relative with breast
cancer were similar: 2.33 (95% CI, 1.76 to 3.08) and 2.26 (95% CI,
1.84 to 2.77), respectively. CHEK2*1100delC carriers had a sig-
niﬁcantly higher risk compared with noncarriers of developing an
Table 2. Breast Cancer Relative Risk Estimates for CHEK2*1100delC Carriers Versus Noncarriers; Tumor Behavior Subgroup and Sensitivity Analyses
Subgroup Case/Control, No. OR 95% CI P
All patients with breast cancer 41,744/39,956 2.44 2.08 to 2.87 6.3 3 10228
Population- and hospital-based patients with breast cancer 36,029/39,464 2.32 1.95 to 2.75 5.5 3 10222
All invasive tumors 39,798/39,956 2.40 2.04 to 2.82 2.0 3 10226
Population- and hospital-based patients with breast cancer,
invasive tumors
34,525/36,464 2.26 1.90 to 2.69 2.3 3 10220
Population- and hospital-based patients with breast cancer,
invasive tumors, incident breast cancers only*
16,702/28,772 2.11 1.69 to 2.65 6.3 3 10211
All in situ tumors† 1,577/34,818 3.53 2.38 to 5.23 3.9 3 10210
Population- and hospital-based patients with breast cancer, in
situ tumors†
1,208/33,379 3.36 2.15 to 5.25 1.0 3 1027
All patients with breast cancer, custom Taqman 39,440/36,596 2.50 2.11 to 2.95 1.2 3 10226
Population- and hospital-based patients with breast cancer,
custom Taqman
34,485/34,466 2.33 1.96 to 2.79 5.5 3 10221
All patients with breast cancer, non-BRCA1/2 carriers only 41,365/39,954 2.46 2.09 to 2.88 2.7 3 10228
Population- and hospital-based patients with breast cancer,
non-BRCA1/2 carriers only
35,872/36,462 2.33 1.96 to 2.76 4.0 3 10222
NOTE. All models were adjusted for age and study.
Abbreviation: OR, odds ratio.
*Incident breast cancer was deﬁned as study entry before and up to 1 year after breast cancer diagnosis.
†Likely biased estimate (see text).
Table 1. Associations of Patient and Tumor Characteristics With CHEK2*1100delC Carriership in Patients With Breast Cancer
Characteristic
Patients From Population- and Hospital-Based Studies
Patients From Familial or Clinical Genetics Center–Based
Studies
Total, No. OR 95% CI P Total, No. OR 95% CI P
Family history* 37,913 1.00 1.00 to 1.00 .44 6,849 1 1.00 to 1.00 .43
Age, years 37,566 0.99 0.98 to 0.99 1.0 3 1023 6,834 0.99 0.98 to 1.01 .37
Tumor behavior 37,571 1.65 1.11 to 2.44 .01 6,775 0.68 0.35 to 1.32 .25
Morphology 30,729 4,831
Ductal Ref Ref
Lobular 0.91 0.68 to 1.22 .52 0.45 0.23 to 0.90 .02
Medullary 0.69 0.25 to 1.88 .46 Omitted
Mixed 1.17 0.69 to 2.00 .56 1.37 0.59 to 3.21 .47
Mucinous 1.02 0.42 to 2.48 .97 Omitted
Other 0.79 0.42 to 1.51 .48 0.69 0.39 to 1.22 .20
Papillary 0.83 0.11 to 6.02 .85 Omitted
Tubular 0.23 0.03 to 1.63 .14 1.14 0.45 to 2.87 .79
Grade 25,808 3,070
I Ref Ref
II 1.32 0.99 to 1.77 .06 1.35 0.77 to 2.36 .30
III 1.13 0.82 to 1.55 .46 1.03 0.57 to 1.87 .91
ER status 26,103 2,532
Negative Ref Ref
Positive 1.92 1.42 to 2.61 2.7 3 1025 2.36 1.24 to 4.48 .01
PR status 21,687 2,372
Negative Ref Ref
Positive 1.37 1.06 to 1.77 .02 1.58 0.95 to 2.63 .08
HER2 status 12,687 655
Negative Ref Ref
Positive 1.03 0.69 to 1.52 .90 0.69 0.24 to 2.01 .50
NOTE. Data given are those included in analyses for eachmodel (Appendix Tables A2 to A5). Homozygous carriers were excluded. Analyses were performed by logistic
regression with CHEK2 as the dependent variable and adjusted for study. For BRCA1/2 mutation status there was insufﬁcient data for the models to run.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; PR, progesterone receptor; Ref, reference category.
*Family history: yes, at least one ﬁrst-degree relative with breast cancer; or no, none.
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ER-positive versus an ER-negative tumor (P = 9.93 1026), with an
OR of 2.55 (95% CI, 2.10 to 3.10; P = 4.93 10221) versus an OR of
1.32 (95%CI, 0.93 to 1.88; P = .12;), respectively. Associations with
PR status were similar to those for ER, but the OR for PR-negative
tumors was higher than that for ER-negative tumors. In the case-
only analysis, there was no association with PR status after adjusting
for ER status (P = .84), whereas CHEK2*1100delC was still asso-
ciated with ER status after adjustment for PR (P = 2.1 3 1024).
There was no association with HER2 status (P = .73; P = .32 after
adjustment for ER).
The relative risk of breast cancer for CHEK2*1100delC car-
riers signiﬁcantly decreased with age for overall (P = .014 for trend)
and for ER-positive disease (P = .026 for trend; Table 3; Appendix
Fig A3). Smoothed age-speciﬁc ORs in years were derived by using
a linear CHEK23 age interaction from a case-only analysis (Fig 2).
There was no evidence for a quadratic (CHEK2 3 age2) term,
which indicated that these models were a reasonable ﬁt (data not
shown). ORs decreased by age for ER-positive disease (OR, 0.86 per
decade; P= .001) but not for ER-negative disease (OR, 0.93; P= .60).
Estimated cumulative risks for ER-positive and ER-negative tumors
by age 80 of CHEK2*1100delC carriers were 20% and 3%, re-
spectively, compared with 9% and 2%, respectively, in the general
population of the United Kingdom (Fig 3).
DISCUSSION
On the basis of analyses of approximately 87,000 controls and
patients with breast cancer from population- and hospital-based
studies, our best estimate for the relative risk of invasive breast
cancer for carriers of the 1100delC mutation in CHEK2, compared
with noncarriers, was 2.26 (95% CI, 1.90 to 2.69). The relative risk
estimates were consistent across studies, which indicates that the
above estimate should be broadly applicable to European women.
Consistent with previous reports,12 the relative risk for
ER-negative breast cancer was markedly lower compared with
ER-positive breast cancer (OR, 1.32 versus 2.55, respectively;
P = 9.9 3 1026), and the ER-negative risk estimate was not
Table 3. Breast Cancer Relative Risk Estimates for CHEK2*1100delC Carriers Versus Noncarriers by Subgroup in Population- and Hospital-Based PatientsWith Breast
Cancer With Invasive Tumors
Subgroup
Total in Case-Control
Analysis, No. OR 95% CI P Case-Control Analysis P Case-Only Analysis
Family history
Negative 31,971 2.04 1.51 to 2.74 2.6 3 1026 .31*
Positive 4,167 1.35 0.71 to 2.56 .36
Age, years
, 35 4,148 2.59 1.23 to 5.47 1.3 3 1022 Ref†
35-50 20,478 2.57 1.83 to 3.59 4.0 3 1028 .17
50-65 31,736 2.36 1.80 to 3.10 6.5 310210 5.3 3 1022
. 65 14,591 1.40 0.93 to 2.12 .11 1.8 3 1022
ER status
Negative 39,850 1.32 0.93 to 1.88 .12 Ref
Positive 52,939 2.55 2.10 to 3.10 4.9 3 10221 9.9 3 1026
PR status
Negative 40,041 1.72 1.29 to 2.30 1.9 3 1024 Ref
Positive 46,648 2.51 2.02 to 3.12 7.6 3 10217 1.7 3 1022
HER2 status
Negative 37,920 2.40 1.88 to 3.06 1.4 3 1022 Ref
Positive 29,584 2.66 1.77 to 4.00 2.7 3 1026 .73
Negative family history by age category, years‡
, 35 967 3.36 0.58 to 19.62 .18 Ref§
35-50 8,181 2.77 1.45 to 5.29 2.0 3 1023 .20
50-65 15,544 2.06 1.33 to 3.19 1.0 3 1023 9.0 3 1023
. 65 7,101 1.26 0.67 to 2.37 .47 2.1 3 1022
ER-negative by age category, years
, 35 2,855 3.02 0.93 to 9.86 6.7 3 1022 Refk
35-50 11,063 1.46 0.77 to 2.75 .25 .62
50-65 17,739 1.48 0.85 to 2.57 .17 .74
. 65 7,826 0.96 0.36 to 2.53 .93 .53
ER-positive by age category, years
, 35 3,262 3.26 1.05 to 10.18 4.2 3 1022 Ref¶
35-50 14,029 3.12 2.13 to 4.58 5.3 3 1029 .20
50-65 24,029 2.73 2.02 to 3.70 6.7 3 10211 8.2 3 1022
. 65 11,597 1.58 1.01 to 2.49 4.6 3 1022 3.2 3 1022
NOTE. All models were adjusted for study and age, except the models that included age as a categorical variable, which were only adjusted for study.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds ratio; PR, progesterone receptor; Ref, reference category.
*P value of interaction term of family history and CHEK2 in case-control analysis.
†Trend test for interaction by including categorical age as a continuous variable in the model P = .014.
‡Insufﬁcient data to derive family history–positive estimates.
§Idem P = .004.
kIdem P = .66.
¶Idem P = .026.
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statistically signiﬁcant. We found neither evidence that risk varied
by PR or HER2 status, after adjustment for ER status, nor any
evidence for variation in relative risk by grade or morphology.
Previous studies have obtained somewhat higher relative
breast cancer risk estimates for CHEK2*1100delC carriers. In
particular, in a previous publication that was based on a subset of
BCAC studies (25,571 patients with breast cancers and 30,056
controls) and that focused on survival in CHEK2*1100delC car-
riers, higher risk estimates were found compared with our study
(overall OR, 3.01 [95% CI, 2.53 to 3.58]; ER-positive OR, 3.47
[95% CI, 2.87 to 4.18]; and ER-negative OR, 1.54 [95% CI, 1.09 to
2.17]).12 However, these estimates were based on fewer data and
were biased as the analyses included clinical genetics–based and
familial studies. Our estimate is also somewhat lower than the
overall estimate in a previously published meta-analysis (OR, 2.7;
95% CI, 2.1 to 3.4)7; however, that meta-analysis also included
fewer individuals, and the higher estimate was largely driven by
relatively high estimates from only two studies.
The relative risk of breast cancer in our study showed amodest
but statistically signiﬁcant decrease by age for breast cancer overall
and for ER-positive disease. Despite the sample size, we had limited
power to derive precise, age-speciﬁc relative risk estimates at young
ages; therefore, to derive more stable, smoothed age-speciﬁc rel-
ative risks, we applied a method in which we estimated a linear
CHEK23 age interaction term from case-only analysis (Fig 2). On
the basis of this model, a woman age 40 years who carries the
CHEK2*1100delC mutation has a relative risk of 3.25 to develop an
ER-positive breast cancer compared with a noncarrier of the same
age, whereas relative risk for a CHEK2*1100delC carrier at age
70 year is 1.87.
Studies on the basis of patients with breast cancer who were
recruited through clinical genetic centers can overestimate the
relative risk that is attributable to a genetic variant because of an
oversampling of patients with a family history of breast cancer.
Indeed, we observed a higher relative risk estimate in women from
clinical genetic–based and familial studies, which emphasized the
fact that population-based studies are required to provide unbiased
relative risk estimates. We assumed that the set of studies that we
included in the main analyses, which were deﬁned in the BCAC
database as hospital- or population-based, provided a sample of
patients with breast cancer and controls that was reasonably
representative of the general population. The proportion of women
with a ﬁrst-degree family history (16.5%) was consistent with that
expected, which suggested that there was little oversampling on the
basis of family that could lead to overestimation of relative risk.
Somewhat surprisingly, in the hospital- and population-based
studies, the relative risk estimate was higher in women without
a ﬁrst-degree relative with breast cancer compared with the risk of
those with family history, but this was not statistically signiﬁcantly
different and disappeared after the exclusion of two studies with
outlier results caused by the study deﬁnitions that were used. In
addition, the risk estimate of 2.04 among women without a family
history was also somewhat lower than that of the overall estimate in
all studies (2.26), which might indicate some selection of studies
for which family history information was available.
We also found that the breast cancer relative risk was lower
for incident invasive breast cancers. This ﬁnding was somewhat
surprising, given that we previously found that CHEK2*1100delC
carriers have a poorer survival compared with noncarriers,12 which
would predict a higher relative risk for incident than prevalent
cancers. This did not seem to be the result of differences in subtype,
as the proportion of ER-positive tumors in incident versus
prevalent tumors was similar (77.8% v 77.0%). Larger follow-up
studies by genotype and tumor subtype might resolve this
discrepancy.
Relative risks in Figure 2 and cumulative risks in Figure 3
provide a basis for counseling. Of note, for all groups, the absolute
risks, which take into account death before breast cancer diagnosis
0.00
0.05
0.10
0.15
0.20
0.25
20 25 30 35 40 45 50 55 60 65 70 75 80
Cu
m
ul
at
iv
e 
Ri
sk
Age (years)
Overall CHEK2*1100delC
Overall general population
ER-Positive CHEK2*1100delC
ER-Positive general population
ER-Negative CHEK2*1100delC
ER-Negative general population
Fig 3. Cumulative breast cancer risks for
CHEK2*1100delC carriers and the general
female population by attained age. ER, es-
trogen receptor.
2756 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Schmidt et al
as a competing event, will be somewhat lower than the cumulative
risks. Breast cancer risks attributed to CHEK2*1100delC carrier-
ship reported in our results would be sufﬁcient to classify such
women in a moderate-risk, but not high-risk, category according
to NICE guidelines in the United Kingdom24; however, a more
appropriate method for use of these data is to incorporate the
estimates into a model that includes the combined effects
of CHEK2*1100delC—and other breast cancer susceptibility
genes—with a polygenic component that models the effect of
other familial factors. This estimation can be accomplished
within the framework of the BOADICEA model, in which the
effects of susceptibility variants and other familial factors are
assumed to combine multiplicatively.25 Such a model can be used
to counsel women with a CHEK2*1100delC mutation, with or
without a family history.
Prompted by high breast cancer risk in homozygous carriers
of CHEK2*1100delC as well as high cumulative risk for female
ﬁrst-degree family members,9,26,27 testing for this mutation has
been already introduced in the Netherlands for female family
members who have been referred for BRCA1/2 counseling and
genetic testing.28 This testing has also been introducted in Ger-
many (R. Schmutzler, personal communication, December 2015)
and Poland (A. Jakubowska, personal communication, December
2015), and other countries, such as Australia (G. Chenevix-Trench,
personal communication, December 2015), are considering similar
steps. Current Dutch guidelines allowCHEK2*1100delC carriers to
be upgraded to more intensive surveillance, without downgrading
of noncarriers.28 Prophylactic measures are generally only dis-
cussed with homozygous carriers.
The current study only provides estimates for theCHEK2*1100delC
mutation. No reliable estimates for other protein-truncating variants in
CHEK2 are yet available, but it might be reasonable to assume that the
relative risk estimates we present for the 1100delC variant can be
applied to carriers of other truncating, though not missense, variants.
The results presented here provide a rational basis for deciding whether
CHEK2 testing should be offered more widely, and for counseling
women who are from families in which one or more members have
received positive test results about the implications for management.
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Excluded persons with non-European
ethnicity by iCOGS genotype (available
for 41,546 samples) or self-reported by
questionnaire (n = 4,720;
within those three CHEK2*1100delC)
Excluded 405 males (no
CHEK2*1100delC) and 217 of unknown
gender (three CHEK2*1100delC)
Invasive tumor
(n = 42,627)
Including (n = 6,363)
from familial
(sub)studies
In situ tumor
(n = 1,734)
Including (n = 419)
from familial
(sub)studies
Unknown
(n = 416)
Including (n = 74)
from familial
(sub)studies
BCAC studies                              (N = 33)
Total European women      (N = 87,774)
Controls                                  (n = 42,997)
Patients with breast cancer (n = 44,777)
Excluded, except for
country rates, two studies
with < 3 CHEK2*1100delC
carriers
(n = 3,373)
BCAC studies (N = 36)
Persons age > 18 years
DNA from blood samples
genotyped for CHEK2*1100delC
Total patients                         (N = 96,489)
Controls                                   (n = 46,574)
Patients with breast cancer   (n = 49,915)
Fig A1. Data ﬂowchart of inclusion and exclusion of patientswith breast cancer and healthy controls from the Breast Cancer Association Consortium (BCAC) database.
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Overall  (I−squared = 19.5%; P = .203) 2.13 (1.77 to 2.56) 100.00
LMBC 3.84 (0.77 to 19.06) 1.34
Study OR (95% CI)
%
Weight
NBCS 2.00 (0.87 to 4.59) 4.99
BBCC 1.07 (0.35 to 3.26) 2.76
SASBAC 1.41 (0.58 to 3.40) 4.38
HABCS 1.08 (0.37 to 3.16) 2.96
SBCS 0.83 (0.28 to 2.42) 2.99
PBCS 2.06 (0.75 to 5.68) 3.33
ABCS 4.92 (2.20 to 11.01) 5.29
HEBCS 2.98 (1.49 to 5.96) 7.15
KBCP 2.47 (0.85 to 7.15) 3.03
MCCS 0.55 (0.11 to 2.76) 1.31
HMBCS 0.92 (0.30 to 2.81) 2.74
GENICA 2.61 (0.93 to 7.34) 3.20
UCIBCS 0.65 (0.18 to 2.34) 2.11
MCBCS 1.70 (0.67 to 4.35) 3.89
OFBCR 3.33 (0.30 to 37.12) 0.59
BSUCH 8.70 (1.99 to 38.05) 1.58
UKBGS 1.77 (0.85 to 3.72) 6.24
SEARCH 2.50 (1.69 to 3.70) 22.49
CGPS 2.44 (1.54 to 3.86) 16.28
ABCFS 3.36 (0.40 to 27.98) 0.76
1.25 .5 1.5 2 2.5 5 10
GESBC 2.56 (0.23 to 28.38) 0.59
Fig A2. Forest plot of odds ratios (ORs) from a ﬁxed meta-analysis of the association between CHEK2*1100delC and invasive breast cancer by study, using population-
and hospital-based studies. ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls;
BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General Population Study; GENICA, Gene Environment Interaction and Breast Cancer in
Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study; HEBCS, Helsinki Breast Cancer Study; HMBCS,
Hannover-Minsk Breast Cancer Study; KBCP, Kuopio Breast Cancer Project; LMBC, Leuven Multidisciplinary Breast Centre; MCBCS, Mayo Clinic Breast Cancer Study;
MCCS, Melbourne Collaborative Cohort Study; NBCS, Norwegian Breast Cancer Study; OFBCR, Ontario Familial Breast Cancer Registry; PBCS, NCI Polish Breast Cancer
Study; SASBAC, Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of Epidemiology and Risk factors in Cancer Heredity;
UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough Generations Study.
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Fig A3. CHEK2*1100delC-associated breast cancer risk per age category: all
invasive and invasive estrogen receptor (ER)–positive disease. P-value trend for all
and ER+ disease: P = .014 and P = .026, respectively (see Table 3).
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Table A1. Study Information, Number of CHEK2*1100delC Genotyped European Women, and Genotyping Assays Used in Each Study
Study Study Name Country Study Design
CHEK2*1100delC
Total,
No.
Type of assay if different
from the custom
Taqman, No.†
Noncarrier,
No.
Heterozygous
Carrier, No.
Homozygous
Carrier, No.*
ABCFS Australian Breast Cancer
Family Study
Australia Population-based case-
control study
2,086 7 0 2,093 Older Taqman assay:
143
ABCS(-F) Amsterdam Breast Cancer
Study
Netherlands Hospital-based
consecutive cases;
population-based
controls; substudy
ABCS-F: patients with
breast cancer recruited
through the clinical
genetic center
3,317 109 6 3,432 Sanger sequencing: 20
BBCC Bavarian Breast Cancer
Cases and Controls
Germany Hospital-based cases;
population-based
controls
1,578 13 0 1,591
BBCS British Breast Cancer
Study
United
Kingdom
English and Scottish
Cancer Registries: all
patients with breast
cancer who developed
a ﬁrst primary age , 65
in 1971 or later and who
subsequently developed
a second primary
cancer; patients with
unilateral breast cancer
diagnosed age , 70 in
1971 or later
2,562 28 0 2,590 Older Taqman assay:
568
BIGGS Breast Cancer in Galway
Genetic Study
Ireland Hospital-based cases;
population based-
controls
1,825 3 0 1,828
BSUCH Breast Cancer Study of the
University of Heidelberg
Germany Hospital-based cases;
healthy blood donator
controls
1,962 23 0 1,985
CGPS Copenhagen General
Population Study
Denmark Consecutive, incident
cases from one hospital
with centralized care for
a population of 400,000
women from 2001 to
present
8,670 80 0 8,750 Older Taqman assay: 12
ESTHER ESTHER Breast Cancer
Study
Germany Statewide recruitment of
breast cancer cases in all
hospitals in Saarland/
Germany in 2001-2003
991 5 0 996
GC-
HBOC
German Consortium for
Hereditary Breast &
Ovarian Cancer
Germany Population-based familial
case-control study
1,936 20 0 1,956
GENICA Gene Environment
Interaction and Breast
Cancer in Germany
Germany Population-based case-
control study
2,005 18 0 2,023
GESBC Genetic Epidemiology
Study of Breast Cancer
by Age 50
Germany Population-based case-
control study
1,194 3 0 1,197 Older Taqman assay:
1,197
HABCS Hannover Breast Cancer
Study
Germany Hospital-based case-
control study
2,026 27 0 2,053 Older Taqman assay: 36
HEBCS Helsinki Breast Cancer
Study
Finland Hospital-based case-
control study and
additional familial cases
3,383 100 1 3,484 Older Taqman assay: 36
HMBCS Hannover-Minsk Breast
Cancer Study
Belarus Hospital-based cases;
population-based
controls
2,811 15 0 2,826 Older Taqman assay: 10
HUBCS Hannover-Ufa Breast
Cancer Study
Russia Hospital-based cases;
population-based
controls
2,393 5 0 2,398 Older Taqman assay: 16
KARBAC Karolinska Breast Cancer
Study
Sweden Population and hospital-
based cases;
geographically matched
controls
1,662 16 0 1,678
KBCP Kuopio Breast Cancer
Project
Finland Population-based
prospective clinical
cohort
888 18 0 906 Older Taqman assay:
906
(continued on following page)
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Table A1. Study Information, Number of CHEK2*1100delC Genotyped European Women, and Genotyping Assays Used in Each Study (continued)
Study Study Name Country Study Design
CHEK2*1100delC
Total,
No.
Type of assay if different
from the custom
Taqman, No.†
Noncarrier,
No.
Heterozygous
Carrier, No.
Homozygous
Carrier, No.*
KConFab/
AOCS
Kathleen Cuningham
Foundation Consortium
for research into Familial
Breast Cancer/
Australian Ovarian
Cancer Study
Australia
and New
Zealand
Clinic-based recruitment of
familial patients with
breast cancer (cases);
population-based case-
control study of ovarian
cancer (controls only)
1,539 13 0 1,552 iPLEX: 1,552
LMBC Leuven Multidisciplinary
Breast Centre
Belgium Hospital-based case-
control study
1,785 14 0 1,799
MCBCS Mayo Clinic Breast Cancer
Study
United
States
Hospital-based case-
control study
2,371 25 2 2,398
MCCS Melbourne Collaborative
Cohort Study
Australia Population-based
prospective cohort study
1,029 7 0 1,036
MSKCC‡ Memorial Sloan Kettering
Cancer Center Study
United
States
Case-control study 947 2 0 949
NBCS Norwegian Breast Cancer
Study
Norway Hospital-based case-
control study
3,483 25 0 3,508
NC-BCFR Northern California Breast
Cancer Family Registry
United
States
Population-based familial
case-control study
531 10 0 541
OFBCR Ontario Familial Breast
Cancer Registry
Canada Population-based familial
case-control study
1,535 11 1 1,547
ORIGO Leiden University Medical
Centre Breast Cancer
Study
Netherlands Hospital-based
prospective cohort study
1,118 36 0 1,154 Oligohybridization assay:
1,154
PBCS NCI Polish Breast Cancer
Study
Poland Population-based case-
control study
4,306 17 0 4,323
RBCS Rotterdam Breast Cancer
Study
Netherlands Hospital based case-
control study,
Rotterdam area
1,519 55 4 1,578 Oligohybridization assay:
13
SASBAC Singapore and Sweden
Breast Cancer Study
Sweden Population-based case-
control study
2,518 20 1 2,539
SBCS Shefﬁeld Breast Cancer
Study
United
Kingdom
Hospital-based case-
control study
1,968 15 0 1,983
SEARCH Study of Epidemiology and
Risk factors in Cancer
Heredity
United
Kingdom
Population-based case-
control study
14,021 131 0 14,152 Older Taqman assay:
1,170
SZBCS IHCC-Szczecin Breast
Cancer Study
Poland Hospital based case-
control study
1,737 6 0 1,743
UCIBCS UCI Breast Cancer Study United
States
Population-based case-
control study
1,407 13 0 1,420
UKBGS UK Breakthrough
Generations Study
United
Kingdom
Population-based cohort
study
4,675 40 0 4,715
US3SS‡ US Three State Study United
States
Population-based case-
control study
2,424 0 0 2,424
Total 90,202 930 15 91,147 Other assay total: 6,833
*Homozygous CHEK2*1100delC carriers were combined with heterozygous carriers for subsequent Appendix Tables.
†Number of samples genotyped only with the speciﬁed assay. See the Data Supplement.
‡Excluded from further analyses, except for estimation of country rates, because of fewer than three CHEK2*1100delC carriers identiﬁed.
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Table A2. Included Numbers and Proportions of CHEK2*1100delC Carriers in Controls and Patients With Breast Cancer
Study
Controls
Patients From Population- and
Hospital-Based Studies
Patients From Familial or Clinical
Genetics Center–Based Studies
No. of
Non-
CHEK2
No. of
CHEK2*1110delC
%
CHEK2*1110delC
No. of
Non-
CHEK2
No. of
CHEK2*1110delC
%
CHEK2*1110delC
No. of
Non-
CHEK2
No. of
CHEK2*1110delC
%
CHEK2*1110delC
ABCFS 729 1 0.1 1,357 6 0.4
ABCS 966 8 0.8 1,375 49 3.4 976 58 5.6
BBCC 743 6 0.8 835 7 0.8
BBCS 1,278 9 0.7 1,284 19 1.5
BIGGS* 877 0.0 948 3 0.3
BSUCH 929 2 0.2 1,033 21 2.0
CGPS 6,171 42 0.7 2,499 38 1.5
ESTHER* 505 0.0 486 5 1.0
GC-
HBOC
1,104 6 0.5 832 14 1.7
GENICA 1,004 5 0.5 1,001 13 1.3
GESBC 634 1 0.2 560 2 0.4
HABCS 986 10 1.0 1,040 17 1.6
HEBCS 1,080 15 1.4 1,800 53 2.9 503 33 6.2
HMBCS 1,013 5 0.5 1,798 10 0.6
HUBCS 1,464 1 0.1 929 4 0.4
KARBAC 863 1 0.1 463 6 1.3 336 9 2.6
KBCP 441 5 1.1 447 13 2.8
KConFab 936 5 0.5 603 8 1.3
LMBC 937 2 0.2 848 12 1.4
MCBCS 1,114 7 0.6 1,257 20 1.6
MCCS 372 3 0.8 657 4 0.6
NBCS 1,867 9 0.5 1,616 16 1.0
NC-BCFR 153 1 0.6 378 9 2.3
OFBCR 343 1 0.3 187 3 1.6 1,005 8 0.8
ORIGO* 86 0.0 1,032 36 3.4
PBCS 2,263 6 0.3 2,043 11 0.5
RBCS 788 9 1.1 731 50 6.4
SASBAC 1,348 9 0.7 1,170 12 1.0
SBCS 986 8 0.8 982 7 0.7
SEARCH 7,100 38 0.5 6,921 93 1.3
SZBCS 851 2 0.2 886 4 0.4
UCIBCS 501 5 1.0 906 8 0.9
UKBGS 2,332 11 0.5 2,343 29 1.2
Total 42,764 233 0.5 37,419 502 1.3 6,648 208 3.0
Abbreviations: ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS,
British Breast Cancer Study; BIGGS, Breast Cancer in Galway Genetic Study; BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General
Population Study; ESTHER, ESTHER Breast Cancer Study; GC-HBOC, German Consortium for Hereditary Breast & Ovarian Cancer; GENICA, Gene Environment
Interaction and Breast Cancer in Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study; HEBCS, Helsinki
Breast Cancer Study; HMBCS, Hannover-Minsk Breast Cancer Study; HUBCS, Hannover-Ufa Breast Cancer Study; KARBAC, Karolinska Breast Cancer Study; KBCP,
Kuopio Breast Cancer Project; KConFab, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer; LMBC, Multidisciplinary Breast Centre;
MCBCS, Mayo Clinic Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NBCS, Norwegian Breast Cancer Study; NC-BCFR, Northern California Breast
Cancer Family Registry; OFBCR, Ontario Familial Breast Cancer Registry; ORIGO, Leiden University Medical Centre Breast Cancer Study; PBCS, NCI Polish Breast
Cancer Study; RBCS, Rotterdam Breast Cancer Study; SASBAC, Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of
Epidemiology and Risk factors in Cancer Heredity; SZBCS, IHCC-Szczecin Breast Cancer Study; UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough
Generations Study.
*Included only in case-only analyses.
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Table A3. Age of Controls at Interview and of Patients With Breast Cancer at Diagnosis
Study
Controls
Patients From Population- and Hospital-Based
Studies
Patients From Familial or Clinical Genetics
Center–Based Studies
No. Mean SD No. Missing No. Mean SD No. Missing No. Mean SD No. Missing
ABCFS 730 41.5 9.6 1,363 42.3 9.2
ABCS 974 37.1 8.0 1,424 42.4 5.1 1,032 44.6 10.3 2
BBCC 749 59.6 12.5 842 54.7 11.7
BBCS 1,287 51.4 9.8 1,303 54.4 8.6
BIGGS 68 63.6 14.5 809 931 52.8 11.5 20
BSUCH 931 56.7 9.8 869 54.6 12.2 185
CGPS 6,213 55.3 12.6 2,537 61.3 12.6
ESTHER 505 62.3 7.1 490 60.8 8.6 1
GC-HBOC 1,110 45.6 14.5 836 46.0 10.9 10
GENICA 1,009 58.2 11.1 1,014 58.1 11.2
GESBC 635 42.7 5.7 562 42.9 5.9
HABCS 993 33.7 12.6 3 1,057 57.4 11.8
HEBCS 1,095 41.2 13.4 1,853 57.5 12.0 536 52.7 12.0
HMBCS 1,016 41.6 12.2 2 1,808 48.9 12.3
HUBCS 1,025 45.7 12.9 440 926 52.3 10.8 7
KARBAC* 864 469 60.6 12.0 342 54.1 12.1 3
KBCP 446 53.3 10.9 459 58.8 14.2 1
KConFab 941 58.0 11.3 611 44.9 9.5
LMBC 935 43.6 9.5 4 815 55.9 12.5 45
MCBCS 1,121 58.8 12.0 1,277 57.3 12.3
MCCS 375 55.1 9.0 661 61.5 9.0
NBCS 1,842 56.2 10.2 34 1,545 55.5 12.2 87
NC-BCFR 154 56.9 4.3 387 54.9 7.4
OFBCR 344 56.9 6.3 190 55.9 6.8 1,013 53.0 10.4
ORIGO* 86 1,068 53.7 10.9
PBCS 2,269 55.8 10.0 2,054 55.8 9.9
RBCS* 797 781 44.4 10.0
SASBAC 1,357 63.3 6.4 1,182 63.1 6.5
SBCS 994 57.6 5.7 989 59.4 12.2
SEARCH 7,136 57.9 9.1 2 7,013 53.2 9.0 1
SZBCS 853 58.4 11.0 890 55.9 11.3
UCIBCS 506 54.9 12.2 914 59.3 12.9
UKBGS 2,343 58.2 9.4 2,372 51.2 9.4
Total 39,956 53.8 12.7 3,041 37,574 54.5 11.8 347 6,841 49.6 11.0 15
NOTE. This table includes all breast cancers irrespective of tumor behavior.
Abbreviations: ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS,
British Breast Cancer Study; BIGGS, Breast Cancer in Galway Genetic Study; BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General
Population Study; ESTHER, ESTHER Breast Cancer Study; GC-HBOC, German Consortium for Hereditary Breast & Ovarian Cancer; GENICA, Gene Environment
Interaction and Breast Cancer in Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study; HEBCS, Helsinki
Breast Cancer Study; HMBCS, Hannover-Minsk Breast Cancer Study; HUBCS, Hannover-Ufa Breast Cancer Study; KARBAC, Karolinska Breast Cancer Study; KBCP,
Kuopio Breast Cancer Project; KConFab, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer; LMBC, Multidisciplinary Breast Centre;
MCBCS, Mayo Clinic Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NBCS, Norwegian Breast Cancer Study; NC-BCFR, Northern California Breast
Cancer Family Registry; OFBCR, Ontario Familial Breast Cancer Registry; ORIGO, Leiden University Medical Centre Breast Cancer Study; PBCS, NCI Polish Breast
Cancer Study; RBCS, Rotterdam Breast Cancer Study; SASBAC, Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of
Epidemiology and Risk factors in Cancer Heredity; SZBCS, IHCC-Szczecin Breast Cancer Study; UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough
Generations Study.
*Included only in case-only analyses.
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Table A4. Behavior of Breast Tumors
Study
Patients From Population- and Hospital-Based Studies Patients From Familial or Clinical Genetics Center–Based Studies
No.* % Invasive % In Situ No. Missing No.* % Invasive % In Situ No. Missing
ABCFS 1,363 100.0
ABCS 1,424 99.9 0.1 1,034 91.7 8.3
BBCC 842 94.4 5.6
BBCS 1,303 100.0
BIGGS 951 94.5 5.5
BSUCH 1,054 98.2 1.8
CGPS 2,537 96.6 3.4
ESTHER 489 99.0 1.0 2
GC-HBOC 846 100.0
GENICA 1,014 100.0
GESBC 556 93.9 6.1 6
HABCS 1,057 98.5 1.5
HEBCS 1,853 93.2 6.8 536 95.0 5.0
HMBCS† 1,808 99.9 0.1
HUBCS† 933 99.9 0.1
KARBAC 469 100.0 345 100.0
KBCP 460 92.0 8.0
KConFab 538 77.7 22.3 73
LMBC 860 98.5 1.5
MCBCS 1,277 84.8 15.2
MCCS 661 100.0
NBCS† 1,584 99.8 0.2 48
NC-BCFR 387 69.3 30.8
OFBCR 190 100.0 1,013 98.3 1.7
ORIGO 1,064 91.5 8.6 4
PBCS 1,968 93.6 6.4 86
RBCS 780 93.6 6.4 1
SASBAC 1,182 100.0
SBCS 956 92.4 7.6 33
SEARCH 7,014 98.0 2.0
SZBCS 732 95.1 4.9 158
UCIBCS 914 85.5 14.6
UKBGS 2,367 96.6 3.4 5
Total 37,579 96.5 3.5 342 6,782 93.8 6.2 74
Abbreviations: ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS,
British Breast Cancer Study; BIGGS, Breast Cancer in Galway Genetic Study; BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General
Population Study; ESTHER, ESTHER Breast Cancer Study; GC-HBOC, German Consortium for Hereditary Breast & Ovarian Cancer; GENICA, Gene Environment
Interaction and Breast Cancer in Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study; HEBCS, Helsinki
Breast Cancer Study; HMBCS, Hannover-Minsk Breast Cancer Study; HUBCS, Hannover-Ufa Breast Cancer Study; KARBAC, Karolinska Breast Cancer Study; KBCP,
Kuopio Breast Cancer Project; KConFab, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer; LMBC, Multidisciplinary Breast Centre;
MCBCS, Mayo Clinic Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NBCS, Norwegian Breast Cancer Study; NC-BCFR, Northern California Breast
Cancer Family Registry; OFBCR, Ontario Familial Breast Cancer Registry; ORIGO, Leiden University Medical Centre Breast Cancer Study; PBCS, NCI Polish Breast
Cancer Study; RBCS, Rotterdam Breast Cancer Study; SASBAC, Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of
Epidemiology and Risk factors in Cancer Heredity; SZBCS, IHCC-Szczecin Breast Cancer Study; UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough
Generations Study.
*Number with data available.
†This study has fewer than ﬁve in situ breast cancers and was excluded from in situ–only analyses.
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Table A5. Receptor Status of Invasive Breast Tumors From Population- and Hospital-Based Breast Cancer Studies
Study
ER PR HER2
No.* Negative, % Positive, % No.* Negative, % Positive, % No.* Negative, % Positive, %
ABCFS 1,168 34.5 65.5 1,164 30.8 69.2
ABCS 936 34.6 65.4 880 48.5 51.5 898 74.8 25.2
BBCC 744 29.3 70.7 741 34.7 65.3 540 83.3 16.7
BIGGS 702 24.9 75.1 556 24.6 75.4 447 79.2 20.8
BSUCH 700 25.1 74.9 699 34.5 65.5 666 82.4 17.6
CGPS 1,758 15.1 84.9 1,267 36.2 63.8 720 84.9 15.1
ESTHER 421 23.8 76.3 415 33.5 66.5 192 72.4 27.6
GENICA 988 22.0 78.0 985 29.8 70.3 707 70.9 29.1
GESBC 443 37.0 63.0 438 39.7 60.3
HABCS 812 15.6 84.4 792 19.6 80.4
HEBCS 1,694 18.2 81.8 1,694 34.8 65.2 916 84.7 15.3
HMBCS 46 30.4 69.6
HUBCS 202 44.1 55.9 202 43.1 56.9 191 49.7 50.3
KARBAC 440 16.8 83.2 385 24.4 75.6
KBCP 389 22.6 77.4 388 38.1 61.9 376 87.2 12.8
LMBC 788 16.2 83.8 783 23.1 76.9 705 84.4 15.6
MCBCS 1,077 16.3 83.8 1,076 25.6 74.4 808 85.0 15.0
MCCS 618 23.3 76.7 621 34.8 65.2 587 82.1 17.9
NBCS 1,314 27.9 72.2 1,286 41.6 58.4 631 88.0 12.0
OFBCR 176 25.0 75.0 175 34.9 65.1
ORIGO 669 26.8 73.2 529 42.2 57.8
PBCS 1,676 33.8 66.2 1,670 47.0 53.0 1,203 82.5 17.5
SASBAC 821 18.0 82.0 799 28.4 71.6
SBCS 540 22.6 77.4 238 39.9 60.1 250 92.0 8.0
SEARCH 5,270 20.2 79.8 2,815 28.5 71.5 2,327 88.6 11.4
SZBCS 657 28.2 71.8 195 60.5 39.5 532 83.8 16.2
UCIBCS 651 20.0 80.0 642 30.4 69.6
UKBGS† 4 25.0 75.0 3 33.3 66.7 2 50.0 50.0
Total 25,704 23.3 76.7 21,438 33.9 66.1 12,698 82.9 17.1
Abbreviations: ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS,
British Breast Cancer Study; BIGGS, Breast Cancer in Galway Genetic Study; BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General
Population Study; ER, estrogen receptor; ESTHER, ESTHER Breast Cancer Study; GC-HBOC, German Consortium for Hereditary Breast & Ovarian Cancer; GENICA,
Gene Environment Interaction and Breast Cancer in Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study;
HEBCS, Helsinki Breast Cancer Study; HER2, human epidermal growth factor receptor 2; HMBCS, Hannover-Minsk Breast Cancer Study; HUBCS, Hannover-Ufa Breast
Cancer Study; KARBAC, Karolinska Breast Cancer Study; KBCP, Kuopio Breast Cancer Project; KConFab, Kathleen Cuningham Foundation Consortium for Research Into
Familial Breast Cancer; LMBC, Multidisciplinary Breast Centre; MCBCS, Mayo Clinic Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NBCS,
Norwegian Breast Cancer Study; NC-BCFR, Northern California Breast Cancer Family Registry; OFBCR, Ontario Familial Breast Cancer Registry; ORIGO, Leiden
University Medical Centre Breast Cancer Study; PBCS, NCI Polish Breast Cancer Study; PR, progesterone receptor; RBCS, Rotterdam Breast Cancer Study; SASBAC,
Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of Epidemiology and Risk factors in Cancer Heredity; SZBCS, IHCC-
Szczecin Breast Cancer Study; UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough Generations Study.
*Number with data available.
†Data from this study were excluded from subtype-speciﬁc analyses adjusted for study.
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Table A6. Family History of Controls and Patients With Breast Cancer
Study
Controls
Patients From Population- and
Hospital-Based Studies
Patients From Familial or Clinical Genetics
Center–Based Studies
No.* No Relative, %
At Least One
Relative, % No.* No Relative, %
At Least One
Relative, % No.* No Relative, %
At Least One
Relative, %
ABCFS 730 93.3 6.7 1,363 82.4 17.6
ABCS† 760 50.7 49.3
BBCC‡ 577 84.4 15.6 787 85.5 14.5
BBCS 979 93.2 6.8 1,302 85.9 14.1
BIGGS† 306 62.1 37.9
BSUCH† 287 86.4 13.6
CGPS† 2,102 80.2 19.8
ESTHER 416 89.4 10.6 438 82.9 17.1
GENICA 1,009 91.9 8.1 1,014 85.4 14.6
GESBC 635 94.0 6.0 562 88.1 11.9
HABCS† 1,024 83.8 16.2
HEBCS† 1,849 76.8 23.2 536 3.5 96.5
HMBCS† 50 94.0 6.0
HUBCS 617 98.7 1.3 907 93.8 6.2
KARBAC† 461 83.7 16.3 320 22.5 77.5
KBCP 446 95.1 4.9 460 88.7 11.3
KConFab 740 89.5 10.5 526 14.4 85.6
LMBC† 760 81.2 18.8
MCBCS 990 81.7 18.3 1,188 78.5 21.5
NBCS 1,021 90.8 9.2 42 78.6 21.4
NC-BCFR 154 85.1 14.9 387 35.1 64.9
OFBCR‡ 341 86.2 13.8 189 93.1 6.9 1,013 53.1 46.9
ORIGO† 891 83.7 16.3
PBCS 2,269 94.2 5.8 2,053 89.4 10.6
RBCS† 781 46.9 53.1
SASBAC 1,233 90.3 9.7 1,152 84.6 15.4
SBCS 994 89.7 10.3 989 85.8 14.2
SEARCH 4,919 93.3 6.7 6,868 83.9 16.1
SZBCS† 853 100.0 890 89.4 10.6
UCIBCS 461 84.2 15.8 913 73.7 26.3
UKBGS§ 4 100.0 19 94.7 5.3
Total 19,388 91.9 8.1 27,564 83.5 16.5 5,625 48.2 51.8
NOTE. Relatives are ﬁrst-degree relatives with breast cancer. This table includes all breast cancers irrespective of tumor behavior.
Abbreviations: ABCFS, Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS,
British Breast Cancer Study; BIGGS, Breast Cancer in Galway Genetic Study; BSUCH, Breast Cancer Study of the University of Heidelberg; CGPS, Copenhagen General
Population Study; ESTHER, ESTHER Breast Cancer Study; GC-HBOC, German Consortium for Hereditary Breast & Ovarian Cancer; GENICA, Gene Environment
Interaction and Breast Cancer in Germany; GESBC, Genetic Epidemiology Study of Breast Cancer by Age 50; HABCS, Hannover Breast Cancer Study; HEBCS, Helsinki
Breast Cancer Study; HMBCS, Hannover-Minsk Breast Cancer Study; HUBCS, Hannover-Ufa Breast Cancer Study; KARBAC, Karolinska Breast Cancer Study; KBCP,
Kuopio Breast Cancer Project; KConFab, Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer; LMBC, Multidisciplinary Breast Centre;
MCBCS, Mayo Clinic Breast Cancer Study; MCCS, Melbourne Collaborative Cohort Study; NBCS, Norwegian Breast Cancer Study; NC-BCFR, Northern California Breast
Cancer Family Registry; OFBCR, Ontario Familial Breast Cancer Registry; ORIGO, Leiden University Medical Centre Breast Cancer Study; PBCS, NCI Polish Breast
Cancer Study; RBCS, Rotterdam Breast Cancer Study; SASBAC, Singapore and Sweden Breast Cancer Study; SBCS, Shefﬁeld Breast Cancer Study; SEARCH, Study of
Epidemiology and Risk factors in Cancer Heredity; SZBCS, IHCC-Szczecin Breast Cancer Study; UCIBCS, UCI Breast Cancer Study; UKBGS, UK Breakthrough
Generations Study.
*Number with data available.
†Included only in case-only analyses.
‡Higher proportion of controls comparedwith cases, either because of overrepresentation of controls with a family history in the subset genotyped forCHEK2 (BBCC) or
because of the case deﬁnition used in the analyses (ie, the subset of nonfamilial cases [OFBCR]).
§Data from this study were excluded from all family history–speciﬁc analyses. Of note, there were no data for MCCS and GC-HBOC.
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Table A8. Breast Cancer Risk Estimates of CHEK2*1100delC Carriers Using Different Models
Model Total, No. OR 95% CI P P *
Carrier model
All patients with breast cancer 81,711 2.48 2.11 to 2.90 7.2 3 10229 .03
Population- and hospital-based patients with breast cancer 72,501 2.36 1.99 to 2.80 5.6 3 10223 .02
Log additive model
All breast patients with cancer 81,711 2.47 2.11 to 2.90 3.7 3 10229 .15
Population- and hospital-based patients with breast cancer 72,501 2.36 1.99 to 2.80 2.1 3 10223 .10
Saturated model
All breast patients with cancer 81,711 2.44 2.08 to 2.87 6.3 3 10228
Population- and hospital-based patients with breast cancer 72,501 2.32 1.95 to 2.75 5.5 3 10222
Carrier model; excluding homozygous CHEK2 carriers
All patients with breast cancer 81,700 2.44 2.08 to 2.87 6.3 3 10228
Population- and hospital-based patients with breast cancer 72,493 2.32 1.95 to 2.75 5.5 3 10222
NOTE. Carrier model: CHEK2 was included as 0 = noncarrier or 1 = carriers; log-additive model, CHEK2 was included as 0 = noncarriers, 1 = heterozygous CHEK2,
2 = homozygous CHEK2; saturated model: CHEK2 was modeled using offset as explained in Patients and Methods.
Abbreviation: OR, odds ratio.
*P value of the model concerned versus the saturated model.
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